Datopotamab Deruxtecan, often abbreviated as DATO, represents a important advancement in targeted cancer therapy. This innovative antibody-drug conjugate combines an monoclonal antibody specifically directed at HER2 positive expressing cells with a potent cytotoxic payload, deruxtecan. The mechanism of action includes the antibody's power to con… Read More